第4回陰性乳がん患者は,新たな医薬品の接着剤に反応する稀な完全免疫反応を達成し,大腫瘍が縮小し,3か月後は検出不能となった. A stage IV triple-negative breast cancer patient achieved a rare complete immune response with a new drug combo, showing major tumor shrinkage and no detectable cancer after three months.

Kazia Terraphuticsは,Paxalieb, pemblozumab, FDAのアクセスプロトコルにより化学療法が実施されたステージ4-3-3-陰性乳がん患者の初期の免疫完全反応を報告した. Kazia Therapeutics reported a rare initial immune-complete response in a stage IV triple-negative breast cancer patient treated with paxalisib, pembrolizumab, and chemotherapy under an FDA expanded access protocol. この患者は3週間で86%の腫瘍削減を達成し,すべての病変の完全新陳代謝解決を3か月で実現し,ICRの基準に合致した. The patient achieved an 86% tumor reduction in three weeks and complete metabolic resolution of all lesions after three months, meeting criteria for an iCR—uncommon in metastatic TNBC. 患者は後続画像処理計画による治療を継続する. The patient remains on treatment with follow-up imaging planned. 同社はまた,パクサリシブの組み合わせ,表遺伝子経路,および液体生検の研究に関する科学発表を発表し,乳がん,免疫腫瘍学,および膠原生体腫の規制戦略の進展を強調した. The company also announced upcoming scientific presentations on paxalisib combinations, epigenetic pathways, and liquid biopsy research, highlighting progress in breast cancer, immuno-oncology, and glioblastoma regulatory strategy.